Business Context and Reporting Period
This Form 8-K is filed by Imprimis Pharmaceuticals, Inc. (noted as Harrow, Inc. in metadata) on November 9, 2016. The report addresses the settlement of insurance claims related to a sprinkler system malfunction that damaged the Company's Texas-based facility in June 2016, shortly before the expected commencement of dispensing finished injectable ophthalmology formulations.
Key Financial Metrics
The filing details a specific insurance settlement rather than standard operating financial metrics such as revenue, profit, or cash flow for a reporting period.
- Total Insurance Settlement: $861,410
- Property Damage Component: $44,613
- Business Interruption Component: $817,797 (covering expected lost profits from July 2016 to a portion of October 2016)
- Deductible Applied: $1,000
The filing text does not provide clear values for the Company's overall revenue, operating margins, debt levels, or liquidity position.
Material Changes
The primary material event is the finalization of the insurance claim settlement. The Company had previously disclosed a decision to cease operations at the Texas facility. The settlement resolves the claims for property damage and business interruption resulting from the June 2016 incident.
Outlook, Risks, and Management Commentary
Management emphasizes that the business interruption recovery amount ($817,797) was determined through negotiation and does not necessarily reflect the actual profit that might have been achieved had the facility remained operational. The Company explicitly states that investors should not interpret the settlement amount as an indication of actual revenues, expenses, or profits the facility would have generated. The settlement covers the period from July 2016 through part of October 2016.
Investor Verification Checklist
- Verify the Company's current operational status regarding the Texas facility and any replacement manufacturing arrangements.
- Confirm the impact of the facility closure on the Company's product launch timeline for injectable ophthalmology formulations.
- Review subsequent filings for actual financial performance to understand the gap between the insurance settlement and potential lost revenue.
- Assess the Company's remaining liquidity and capital resources following the cessation of operations at the Texas site.